Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
OBJECTIVE
The objectives of this study were twofold: (1) to estimate the anti-tumor efficacy of CI-958 in patients with measurable platinum-resistant ovarian cancer; (2) to determine the nature and degree of toxicity of CI-958 in these patients.


METHODS
Patients received CI-958 560 mg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles.


RESULTS
In 25 cases with recurrent platinum-resistant disease, there was one partial response (PR) and six patients had stable disease (SD).


CONCLUSIONS
CI-958 has minimal activity in platinum-resistant ovarian cancer at the dose and schedule tested.
Hoffman
M A
MA
Division of Hematology-Oncology, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA.
Blessing
J A
JA
Morgan
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D007191:Indazoles; D009944:Organoplatinum Compounds; C054558:ledoxantrone